

# Francesco Rodeghiero

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8259882/publications.pdf>

Version: 2024-02-01

109  
papers

12,541  
citations

53660

45  
h-index

28224

105  
g-index

114  
all docs

114  
docs citations

114  
times ranked

7347  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune thrombocytopenia in myeloid and lymphoid clonal disorders: an intriguing association. <i>Haematologica</i> , 2021, 106, 1231-1233.	1.7	2
2	Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study. <i>British Journal of Haematology</i> , 2021, 193, 386-396.	1.2	23
3	PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021032.	0.5	17
4	Thrombosis in immune thrombocytopenia – current status and future perspectives. <i>British Journal of Haematology</i> , 2021, 194, 822-834.	1.2	31
5	Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia. <i>Blood</i> , 2021, 138, 571-583.	0.6	26
6	Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2348-2354.	1.9	7
7	Management of immune thrombocytopenia in women: current standards and special considerations. <i>Expert Review of Hematology</i> , 2020, 13, 175-185.	1.0	20
8	Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. <i>Thrombosis Research</i> , 2020, 185, 88-95.	0.8	7
9	Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. <i>Expert Review of Hematology</i> , 2020, 13, 1319-1332.	1.0	10
10	Cerebral microbleeds in ITP: alarming or innocent?. <i>Blood</i> , 2020, 136, 2842-2844.	0.6	0
11	Thrombopoietin receptor agonists: ten years later. <i>Haematologica</i> , 2019, 104, 1112-1123.	1.7	219
12	Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (<sc>ITP</sc>) for up to 1 year and in those with chronic <sc>ITP</sc> for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. <i>British Journal of Haematology</i> , 2019, 185, 503-513.	1.2	49
13	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Advances</i> , 2019, 3, 3780-3817.	2.5	593
14	Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study. <i>Blood</i> , 2019, 134, 1708-1711.	0.6	16
15	A comparative prospective observational study of children and adults with immune thrombocytopenia: 2-year follow-up. <i>American Journal of Hematology</i> , 2018, 93, 751-759.	2.0	38
16	A critical appraisal of the evidence for the role of splenectomy in adults and children with <sc>ITP</sc>. <i>British Journal of Haematology</i> , 2018, 181, 183-195.	1.2	58
17	Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers. <i>American Journal of Hematology</i> , 2018, 93, 58-64.	2.0	31
18	Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia. <i>Journal of Hematology (Brossard, Quebec)</i> , 2018, 7, 87-95.	0.4	3

#	ARTICLE	IF	CITATIONS
19	Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists. <i>Annals of Hematology</i> , 2017, 96, 1421-1434.	0.8	33
20	Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. <i>Haematologica</i> , 2017, 102, 1342-1351.	1.7	51
21	A hit to current "wisdom": A century later, it's time for a change. <i>American Journal of Hematology</i> , 2017, 92, 727-729.	2.0	1
22	ITP and thrombosis: an intriguing association. <i>Blood Advances</i> , 2017, 1, 2280-2280.	2.5	29
23	Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia. <i>Annals of Hematology</i> , 2016, 95, 1077-1087.	0.8	43
24	Is <sc>ITP</sc> a thrombophilic disorder?. <i>American Journal of Hematology</i> , 2016, 91, 39-45.	2.0	114
25	Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. <i>American Journal of Hematology</i> , 2016, 91, 995-1001.	2.0	53
26	Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome. <i>Annals of Hematology</i> , 2016, 95, 863-870.	0.8	14
27	Thrombotic risk in patients with immune haemolytic anaemia. <i>British Journal of Haematology</i> , 2016, 172, 144-146.	1.2	14
28	The European Hematology Association Roadmap for European Hematology Research: a consensus document. <i>Haematologica</i> , 2016, 101, 115-208.	1.7	67
29	Treatment of Immune Thrombocytopenia in Adults: The Role of Thrombopoietin-Receptor Agonists. <i>Seminars in Hematology</i> , 2015, 52, 16-24.	1.8	31
30	Von Willebrand disease. <i>Hematology</i> , 2014, 19, 370-371.	0.7	1
31	Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1266-1273.	1.9	95
32	Inhibitor development: The last enemy to be defeated in hemophilia A and B. <i>American Journal of Hematology</i> , 2014, 89, 569-570.	2.0	0
33	Autoimmune cytopenias in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2014, 89, 1055-1062.	2.0	93
34	ITP and international guidelines: What do we know, what do we need?. <i>Presse Medicale</i> , 2014, 43, e61-e67.	0.8	39
35	Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. <i>Blood</i> , 2014, 124, 2930-2936.	0.6	268
36	B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2013, 88, 32-36.	2.0	36

#	ARTICLE	IF	CITATIONS
37	Von Willebrand disease: Pathogenesis and management. <i>Thrombosis Research</i> , 2013, 131, S47-S50.	0.8	13
38	Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2013, 88, 277-282.	2.0	17
39	The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2013, 88, 289-293.	2.0	19
40	Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1442-1449.	0.8	167
41	Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. <i>American Journal of Hematology</i> , 2013, 88, 955-960.	2.0	14
42	Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. <i>European Journal of Haematology</i> , 2013, 91, 423-436.	1.1	90
43	Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. <i>Blood</i> , 2013, 121, 2596-2606.	0.6	179
44	Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. <i>Haematologica</i> , 2013, 98, 875-880.	1.7	97
45	The expert in hemostasis and thrombosis in the Italian health system: role and requirements for a specific clinical and laboratory expertise. <i>Italian Journal of Medicine</i> , 2013, 7, 71.	0.2	0
46	The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. <i>Blood Cells, Molecules, and Diseases</i> , 2012, 48, 68-75.	0.6	28
47	Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines. <i>Leukemia and Lymphoma</i> , 2012, 53, 2262-2268.	0.6	18
48	TPO-receptor agonists in ITP: A clinician's navigation between scylla and charybdis. <i>American Journal of Hematology</i> , 2012, 87, 943-943.	2.0	5
49	Short- and long-term risks of splenectomy for benign haematological disorders: should we revisit the indications?. <i>British Journal of Haematology</i> , 2012, 158, 16-29.	1.2	99
50	Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. <i>American Journal of Hematology</i> , 2012, 87, 203-204.	2.0	29
51	Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. <i>Thrombosis and Haemostasis</i> , 2011, 105, 647-654.	1.8	44
52	Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. <i>Haematologica</i> , 2011, 96, 1831-1837.	1.7	118
53	Advances in the diagnosis and management of type 1 von Willebrand disease. <i>Expert Review of Hematology</i> , 2011, 4, 95-106.	1.0	8
54	Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status. <i>Haematologica</i> , 2010, 95, 1230-1232.	1.7	33

#	ARTICLE	IF	CITATIONS
55	Treatment outcome in a cohort of young patients with polycythemia vera. <i>Internal and Emergency Medicine</i> , 2010, 5, 411-413.	1.0	8
56	Treatment practices in adults with chronic immune thrombocytopenia – a European perspective. <i>European Journal of Haematology</i> , 2010, 84, 160-168.	1.1	23
57	Identical IGHV gene rearrangement may precede the clinical onset of chronic lymphocytic leukemia by several years. <i>American Journal of Hematology</i> , 2010, 85, 868-871.	2.0	6
58	ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2063-2065.	1.9	607
59	The impact of bleeding history, von Willebrand factor and PFA <sup>100</sup> on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM <sup>1</sup> VWD. <i>British Journal of Haematology</i> , 2010, 151, 245-251.	1.2	41
60	Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia. <i>New England Journal of Medicine</i> , 2010, 363, 1889-1899.	13.9	374
61	International consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood</i> , 2010, 115, 168-186.	0.6	1,802
62	Optimizing treatment of von Willebrand disease by using phenotypic and molecular data. <i>Hematology American Society of Hematology Education Program</i> , 2009, 2009, 113-123.	0.9	17
63	The revival of clinical wisdom: The case of oral anticoagulation management. <i>American Journal of Hematology</i> , 2009, 84, 546-547.	2.0	0
64	Response: Immune thrombocytopenic purpura: terminology and definitions. <i>Blood</i> , 2009, 114, 2004-2004.	0.6	2
65	Thrombosis associated with angiogenesis inhibitors. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 115-128.	0.7	100
66	Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. <i>Blood</i> , 2009, 113, 2386-2393.	0.6	2,128
67	Immune Thrombocytopenia in Lymphoproliferative Disorders. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 1261-1274.	0.9	24
68	How I treat von Willebrand disease. <i>Blood</i> , 2009, 114, 1158-1165.	0.6	79
69	The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. <i>Blood</i> , 2009, 114, 3167-3172.	0.6	216
70	Is splenectomy still the gold standard for the treatment of chronic ITP?. <i>American Journal of Hematology</i> , 2008, 83, 91-91.	2.0	39
71	Flow cytometry in the diagnosis of drug-induced thrombocytopenia: Two illustrative cases. <i>American Journal of Hematology</i> , 2008, 83, 326-329.	2.0	5
72	Hemostatic complications of angiogenesis inhibitors in cancer patients. <i>American Journal of Hematology</i> , 2008, 83, 862-870.	2.0	62

#	ARTICLE	IF	CITATIONS
73	First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat. <i>European Journal of Haematology</i> , 2008, 80, 19-26.	1.1	35
74	Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature. <i>Haematologica</i> , 2008, 93, 98-103.	1.7	59
75	Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. <i>Haematologica</i> , 2008, 93, 372-380.	1.7	316
76	Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. <i>Blood</i> , 2008, 111, 3998-4003.	0.6	71
77	Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. <i>Blood</i> , 2008, 111, 3531-3539.	0.6	187
78	Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD). <i>Blood</i> , 2008, 111, 4979-4985.	0.6	148
79	Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. <i>Blood</i> , 2008, 111, 1110-1116.	0.6	93
80	A Prospective Evaluation of Bleeding Tendency and Efficacy of Antihemorrhagic Treatments in Patients with Increased Von Willebrand Factor (VWF) Clearance (Von Willebrand Disease Vicenza AND C1130F) <i>Tj ETQqO 00.6gBT /Oerlock 10</i>	0.6	10
81	Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. <i>Blood</i> , 2007, 109, 1401-1407.	0.6	249
82	Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). <i>Blood</i> , 2007, 109, 112-121.	0.6	364
83	Recurrent Venous Thrombosis in Patients with Polycythemia Vera and Essential Thrombocythemia. <i>Clinical Leukemia</i> , 2007, 1, 339-344.	0.2	1
84	Assessing bleeding in von Willebrand disease with bleeding score. <i>Blood Reviews</i> , 2007, 21, 89-97.	2.8	66
85	Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 715-721.	1.9	54
86	Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: A critical appraisal from literature analysis. <i>Pediatric Blood and Cancer</i> , 2006, 47, 653-656.	0.8	16
87	Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. <i>American Journal of Hematology</i> , 2006, 81, 426-431.	2.0	59
88	The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2619-2626.	1.9	317
89	Treatment of von Willebrand disease. <i>Seminars in Hematology</i> , 2005, 42, 29-35.	1.8	40
90	The Incidence of Chronic Lymphocytic Leukemia in the General Population.. <i>Blood</i> , 2004, 104, 2809-2809.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. <i>Haematologica</i> , 2003, 88, 94-108.	1.7	141
92	Idiopathic thrombocytopenic purpura: an old disease revisited in the era of evidence-based medicine. <i>Haematologica</i> , 2003, 88, 1081-7.	1.7	27
93	Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. <i>American Journal of Hematology</i> , 2002, 71, 1-6.	2.0	78
94	Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma. <i>Haematologica</i> , 2002, 87, 1157-64.	1.7	11
95	Congenital von Willebrand disease type 1: definition, phenotypes, clinical and laboratory assessment. <i>Best Practice and Research in Clinical Haematology</i> , 2001, 14, 321-335.	0.7	37
96	Pregnancy in Women with Type 1 von Willebrand Disease Caused by Heterozygosity for von Willebrand Factor Mutation C1130F. <i>Thrombosis and Haemostasis</i> , 2000, 84, 351-352.	1.8	27
97	Inconsistency of Association between Type 1 von Willebrand Disease Phenotype and Genotype in Families Identified in an Epidemiological Investigation. <i>Thrombosis and Haemostasis</i> , 1999, 82, 1065-1070.	1.8	98
98	Homocysteine levels in polycythaemia vera and essential thrombocythaemia. <i>British Journal of Haematology</i> , 1999, 105, 551-555.	1.2	39
99	Activated Protein C Resistance and Factor V Leiden Mutation Are Independent Risk Factors for Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 1999, 130, 643.	2.0	199
100	The Epidemiology of Inherited Thrombophilia: the VITA Project. <i>Thrombosis and Haemostasis</i> , 1997, 78, 636-640.	1.8	52
101	The VITA Project: Phenotypic Resistance to Activated Protein C and FV Leiden Mutation in the General Population. <i>Thrombosis and Haemostasis</i> , 1997, 78, 859-863.	1.8	34
102	Prospective Multicenter Study on Subcutaneous Concentrated Desmopressin for Home Treatment of Patients with von Willebrand Disease and Mild or Moderate Hemophilia A. <i>Thrombosis and Haemostasis</i> , 1996, 76, 692-696.	1.8	84
103	Factor VIII: C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease. <i>British Journal of Haematology</i> , 1995, 89, 147-151.	1.2	43
104	Hydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis. <i>New England Journal of Medicine</i> , 1995, 332, 1132-1137.	13.9	787
105	Current Management of von Willebrand's Disease. <i>Drugs</i> , 1995, 50, 602-614.	4.9	20
106	Desmopressin-induced thrombocytopenia in type I platelet discordant von Willebrand disease. <i>American Journal of Hematology</i> , 1993, 43, 5-9.	2.0	17
107	Replacement Therapy with Virus-Inactivated Plasma Concentrates in von Willebrand Disease. <i>Vox Sanguinis</i> , 1992, 62, 193-199.	0.7	79
108	Von Willebrand Factor Antigen Is Less Sensitive than Ristocetin Cofactor for the Diagnosis of Type I von Willebrand Disease -Results Based on an Epidemiological Investigation. <i>Thrombosis and Haemostasis</i> , 1990, 64, 349-352.	1.8	36

#	ARTICLE	IF	CITATIONS
109	Von Willebrand Disease. , 0, , 51-61.		3